Irinotecan and Mitomycin C in 5-Fluorouracil-Refractory Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|60|2|127-133

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.2, 2001-02, pp. : 127-133

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicenter Phase I Study of Irinotecan plus Raltitrexed in Patients with 5-Fluorouracil-Refractory Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 42-47

Karger

Access to resources Recommend Favorite

The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 254-265

Karger

Access to resources Recommend Favorite

Gefitinib in Combination with Oxaliplatin and 5-Fluorouracil in Irinotecan-Refractory Patients with Colorectal Cancer: A Phase I Study of the Arbeits gemeinschaft Internistische Onkologie (AIO)

By  

Oncology Research and Treatment, Vol. 31, Iss. 5, 2008-04 ,pp. : 237-241

Karger

Access to resources Recommend Favorite

Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer

By  

Oncology, Vol. 83, Iss. 2, 2012-06 ,pp. : 57-66

Karger

Access to resources Recommend Favorite